Vega I.
- Country
- Spain
- Department
- Oncolgy
Research Overview
- Phase III Randomized Controlled Trial of Abemaciclib Plus Endocrine Therapy Versus Endocrine Therapy in HR+/HER2- Early Breast Cancer with Intermediate to High Risk
- Evaluation of Trastuzumab and Pertuzumab with FDG-PET Response-Adapted Strategy in HER2-Positive Breast Cancer: The PHERGain Study
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
Data & Insights
Has run more than one trial at 123 of 395 partner sites.
Specializations
Early-Stage Breast Cancer Research
The investigator specializes in studying treatments for early-stage breast cancer, with particular emphasis on hormone receptor-positive (HR+) and HER2-negative disease variants.
- Adjuvant endocrine therapy optimization
- Response-adaptive treatment strategies
- Personalized therapeutic approaches
Their work includes evaluation of novel therapeutic agents in combination with standard endocrine treatments.
Advanced Breast Cancer Studies
Focus areas include metastatic breast cancer and locally advanced disease, investigating innovative treatment combinations and targeted therapies.
- CDK4/6 inhibitor therapies
- ESR1-mutation targeted treatments
- Novel drug combinations
Research encompasses both hormone receptor-positive and triple-negative disease subtypes.
HER2-Positive Disease Management
Expertise in HER2-positive breast cancer treatment modalities, including investigation of targeted therapies and immunotherapeutic approaches.
- Chemotherapy-free strategies
- Targeted antibody therapies
- Treatment response monitoring
The research includes evaluation of novel therapeutic sequences and combinations for optimal disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.